Crowdfunding
Three Crowdfunding Platforms Authorized by Consob: Next Equity, Optimart and Pariter Equity
Three crowdfunding platforms, Next Equity, Pariter Equity, and Optimart, have been authorized under European Regulation. Next Equity, founded by Michela Centioni, has raised 3.5 million euros since 2015. Pariter Equity, started in 2020 by Pariter Partners, uses a “Syndicate Investing” model. Optimart, focusing on art projects, has financed 126 projects worth 1.3 million euros.
Three other crowdfunding platforms have been authorized in recent days to operate according to the European Regulation.
These are Next Equity, a historic equity crowdfunding platform, Pariter Equity, founded by the investment company Pariter Partners and Optimart, a lending crowdfunding platform active in the art sector.
Crowdfunding platform MF Next Equity
Authorized pursuant to the new EU regulation on 12 June, MF Next Equity was one of the first platforms in Italy to obtain Consob authorization in 2014. It was founded by Michela Centioni who, still today, is leads as CEO. From 2015 to November 2023, the platform launched 16 campaigns, 9 of which were successfully closed, raising a total of 3.5 million euros.
Next Equity’s greatest success is related to the Synbiotec campaign which, in 2016, was the first in Italy to raise 1 million euros.
In November 2021 Milano Finanza Editori entered the capital of the platform which thus changed its name to MF Next Equity.
Pariter Equity
The equity crowdfunding platform Pariter Equity was authorized by Consob and the Bank of Italy last June 5th.
Pariter Equity was founded and is controlled by the investment company Pariter Partners, created by Jari Ognibeni and Matteo Elli.
The platform, born in 2020, offers the “Syndicate Investing” model: for each project an investment vehicle (SRL) is created which allows investors to co-invest with “lead investors” in the best startups on the market.
Optimart
Optimart, a lending crowdfunding platform, was authorized on June 12, to operate with the new regulation.
The platform aims to support the world of art, especially Italian, through projects to enhance the works and therefore the artists themselves. The projects are financed through peer-to-peer loans with interest rates from 3.3 to 8% and with a duration of typically 36 months.
From 2022 to November 2023, before the interruption due to the authorization process, the platform helped finance 126 artistic projects for over 1.3 million, with an average collection of just under €14,000 per project.
__
(Featured image by Guillame Perigois via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Crowdfunding buzz. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us
-
Cannabis2 weeks ago
Debunking Myths: The Truth About Medical Cannabis and Its Impact on Brain Health
-
Biotech6 days ago
Oryzon up 3% After Progress in Trial of Its Drug for Personality Disorder
-
Business2 weeks ago
The Nuanced Differences That Make Specific Online Casinos Stand Apart From Others
-
Biotech4 days ago
Alfasigma Gets Green Light for Commercialization of Jyseleca in Europe